40 /100
MEDIUM RISK
Score updated Jul 13, 2026

GRCE — Grace Therapeutics, Inc. Dilution Risk Tracker

Track GRCE dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track GRCE — Get alerts when the score changes →

As of July 13, 2026, Grace Therapeutics, Inc. (GRCE) has a DilutionWatch DilutionScore of 40/100, rated MEDIUM dilution risk. Grace Therapeutics, Inc. has a market capitalization of $39.77M, 16.27M shares outstanding, 35 institutional holders tracked. Key dilution vectors include approximately 12 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
46
💰 Cash Runway
40
📊 Float Risk
30
⚠️ Warrant Exposure
40
🔄Convertible Debt—

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for GRCE.
🔔 Track GRCE — Get forecast alerts →

💹 Market Data

Market Cap$39.77M
Shares Outstanding16.27M
Float12.79M
Cash$16.99M
DebtN/A
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↓ 12.0% shares (2026Q1 vs prior)
35 institutional holders · 4.81M shares
#1 Cerity Partners LLC 849.1K shares
#2 VANGUARD CAPITAL MANAGEMENT LLC 803.3K shares
#3 Eversept Partners, LP 756.6K shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest1.71M
Days to Cover5.1
% of Float13.3%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Mar 31, 2026
Full SEC filing analysis available with free account →

📰 Recent News

Sector Update: Health Care Stocks Edge Lower Late Afternoon MT Newswires · Apr 23
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-10 GlobeNewswire · Apr 23
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Resul GlobeNewswire · Apr 14

📋 What This Means for GRCE Shareholders

Grace Therapeutics, Inc. (GRCE) has a DilutionScore of 40/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 13, 2026.

Cash runway is a key watch item: GRCE has approximately 12 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for GRCE in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for GRCE alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track GRCE Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking GRCE — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

AAT ACH AHRT ALOT AMPH

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for GRCE
📊 GRCE FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 GRCE Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.